Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Convalescent plasma therapy in patients with COVID-19.
Yiğenoğlu TN, Hacıbekiroğlu T, Berber İ, Dal MS, Baştürk A, Namdaroğlu S, Korkmaz S, Ulas T, Dal T, Erkurt MA, Turgut B, Altuntaş F. Yiğenoğlu TN, et al. Among authors: ulas t. J Clin Apher. 2020 Aug;35(4):367-373. doi: 10.1002/jca.21806. Epub 2020 Jul 9. J Clin Apher. 2020. PMID: 32643200 Free PMC article. Review.
Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients.
Yiğenoğlu TN, Başcı S, Şahin D, Ulaş T, Dal MS, Korkmaz S, Hacıbekiroğlu T, Namdaroğlu S, Erkurt MA, Turgut B, Altuntaş F. Yiğenoğlu TN, et al. Among authors: ulas t. Transfus Apher Sci. 2021 Dec;60(6):103237. doi: 10.1016/j.transci.2021.103237. Epub 2021 Aug 17. Transfus Apher Sci. 2021. PMID: 34419356 Free PMC article. Review.
Efficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: A Multicenter Experience in Turkey.
Kalpakci Y, Hacibekiroglu T, Darcin T, AkgunCagliyan G, Cakar MK, Hacioglu SK, Ekinci O, Korkmaz S, Albayrak M, Dal MS, Dogan A, Ulas T, Eser B, Altuntas F. Kalpakci Y, et al. Among authors: ulas t. Transfus Apher Sci. 2021 Oct;60(5):103244. doi: 10.1016/j.transci.2021.103244. Epub 2021 Aug 25. Transfus Apher Sci. 2021. PMID: 34462219
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.
Akpinar S, Dogu MH, Celik S, Ekinci O, Hindilerden IY, Dal MS, Davulcu EA, Tekinalp A, Hindilerden F, Ozcan BG, Hacibekiroglu T, Erkurt MA, Bagci M, Namdaroglu S, Korkmaz G, Bilgir O, Cagliyan GA, Ozturk HBA, Serin I, Tiryaki TO, Ozatli D, Korkmaz S, Ulas T, Eser B, Turgut B, Altuntas F. Akpinar S, et al. Among authors: ulas t. Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):169-173. doi: 10.1016/j.clml.2021.09.010. Epub 2021 Sep 15. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34629286
191 results